Drug plus clot removal for large vessel stroke
Part of Brain & nervous system, Heart & circulation clinical trials.
This study tests whether adding a drug called human urinary kallidinogenase to standard clot-removal therapy helps people recover better after a large-vessel stroke. If you qualify, you would receive the drug or a placebo by IV along with the procedure, and doctors will monitor your recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a stroke caused by a large blockage in the front part of your brain and are getting a clot-removal procedure within 24 hours.
- You are 18 or older and were independent before the stroke (could do daily tasks without help).
- Your brain scan shows a moderate-sized area of damage (infarct core between 10 and 100 mL) and enough surrounding brain tissue at risk.
- You do not have severe heart, liver, or kidney problems, a bleeding risk, or allergies to the study drug or contrast dye.
- You are not pregnant or breastfeeding, and you are willing to follow the study schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a drug called human urinary kallidinogenase to standard clot-busting therapy with reteplase improves outcomes for people having a first or recurrent ischemic stroke. It is designed for patients who can start treatment within 4.5 hours of symptoms and have moderate stroke severity.
This trial tests if adding a drug called human urinary kallidinogenase (HUK) can improve recovery for people who have had a stroke and already received clot-busting medicine or a procedure to remove the clot. The goal is to see if it helps reduce disability after a stroke.
This trial tests a drug called Human Urinary Kallidinogenase to see if it can help people recover better after a recent stroke caused by a blockage in the front part of the brain. It is for patients who have mild to moderate symptoms and can start treatment within 2 days of the stroke.
This trial tests a drug called urinary kallidinogenase to see if it helps people who have had a stroke caused by a large artery in the brain becoming narrowed or blocked. It is for those who can be treated within 48 hours of symptoms starting.
This trial tests whether a medicine called human urinary kallidinogenase can reduce inflammation after a stroke. It may help people who have had a first or recent stroke and have certain levels of disability.
This trial tests giving a clot-dissolving medicine (rhPro-UK) through a vein before a procedure to remove a large blood clot in the brain. It is for people who had a stroke 4.5 to 24 hours ago and are already scheduled for clot removal. The goal is to see if the medicine helps improve blood flow and outcomes.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.